RIVERSIDE, CA--(Marketwire - December 18, 2012) - Ingen Technologies, Inc. (PINKSHEETS: IGNT), an emerging medical device manufacturer with patented proprietary medical technology for the growing $55 Billion US home healthcare industry, is pleased to announce new purchase orders from major medical suppliers.
"As a part of our growth plan moving forward, I am pleased to announce new sizable purchase orders received from Qosina Corporation, Oximed Inc. and Jameson Medical. The purchase orders have been fulfilled and delivered. These are very strong indicators of meeting revenue expectations for our product sales. Our Oxyview technology and Smart Nasal Cannula product line have the endorsement from the COPD-ALERT Foundation. I will continue to keep all of our shareholders informed of these major milestones," stated Gary B. Tilden, Chairman of the Board.
Ingen's marketing efforts are focused on Sam's Club's e-commerce medical supplies program, and finalizing a government contract supplier, as a part of our GSA Contract Award to distribute our Oxyview and Smart Nasal Cannula to the Department of Defense facilities and to VA Hospitals.
Wall Street's leading independent micro-cap research firm considers a STRONG BUY recommendation and a 12-month price target of $.15 per share for Ingen. The entire research report is available at http://www.otcmarkets.com/stock/IGNT/research.
An excerpt from the report states, "IGNT common stock is valued at $0.15 per share, 2727% higher than the current market price of $0.0055 per share. The stock is an interesting short term trade and potentially a good long term investment."
VISIT OUR WEBSITE AT: www.ingen-tech.com or FACT SHEET AT: http://ingen-tech.com/files/documents/ignt-1112.pdf
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.